Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis

P. A. Klimiuk, S. Sierakowski, R. Latosiewicz1, B. Cylwik2, J. Skowronski1 and J. Chwiecko

Department of Rheumatology and Internal Diseases,
1 Department of Orthopaedic Surgery and
2 Department of Pathological Anatomy, Medical University of Bialystok, Bialystok, Poland


    Abstract
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Objective. Rheumatoid synovitis is characterized by an invasive and tissue-destructive infiltrate of lymphocytes, macrophages and synoviocytes. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) produced by these cells are important in the remodelling of the articular tissues in rheumatoid arthritis (RA). The aim of this study was to explore whether the serum concentrations of MMPs and their inhibitors were correlated with the histological appearance of the disease.

Methods. Tissue and serum samples were obtained from 37 patients with clinically active RA and 30 with osteoarthritis (OA). Morphological analysis allowed the division of RA synovial specimens into two distinct types. In 22 samples only diffuse infiltrates of mononuclear cells without further microanatomical organization were found. In 15 specimens we observed lymphocytic conglomerates with germinal centre-like structures. Serum concentrations of interstitial collagenase (MMP-1), stromelysin-1 (MMP-3), gelatinase B (MMP-9), TIMP-1 and TIMP-2 were measured with an ELISA technique.

Results. Unique serum profiles of MMPs and TIMPs were identified in each of the two histological types of RA synovitis. The serum concentrations of MMP-1, MMP-3 and MMP-9 were higher in RA patients than in OA patients used as a control group (P<0.001 for all comparisons). These three MMPs dominated in the serum of RA patients with follicular synovitis compared with those with diffuse synovitis (P<0.05, P<0.01 and P<0.001 respectively). The analysis of the serum concentrations of TIMP-1 and TIMP-2 showed that their levels were also elevated in RA patients compared with OA patients (P<0.001 and P<0.01 respectively). Only TIMP-1 was found in a significantly higher concentration in the serum of RA patients with follicular synovitis than in those with diffuse synovitis (P<0.05). The serum concentrations of MMPs and TIMP-1 clearly identified patients with two different histological types of rheumatoid synovitis and with OA. Additionally, the analysis of clinical data showed that the rheumatoid disease in patients with follicular synovitis seemed to be more active than in those with diffuse synovitis.

Conclusion. The morphological appearance of rheumatoid synovitis and the serum MMP and TIMP-1 profile were correlated with the clinical activity of the disease, confirming the heterogeneity of RA. These associations also suggest that patients with different histological forms of RA might require different treatment regimens.

KEY WORDS: Matrix metalloproteinases, MMPs, Tissue inhibitors of metalloproteinases, TIMPs, Rheumatoid arthritis, Histology, Heterogeneity.


    Introduction
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Rheumatoid arthritis (RA) is characterized by chronic inflammation with progressive articular damage and is often associated with systemic manifestations. Lymphocytes, macrophages and synoviocytes infiltrating the synovium have been reported to be involved in this process. The histomorphological changes also include neoangiogenesis and the proliferation of the synovium lining layer [14]. Tissue destruction is caused by several mechanisms, including the production of monokines and matrix metalloproteinases (MMPs) [1, 46]. MMP production in fibroblasts, macrophages and chondrocytes is mediated by synovial macrophages and lymphocytes [68]. MMPs are the proteases that participate in the degradation and remodelling of the extracellular matrix. Tissue inhibitors of metalloproteinases (TIMPs) control their action [5, 6, 9].

Several investigators have shown genetic, histological, biological and clinical heterogeneity of RA [1014]. However, the associations between the morphological components of RA synovium and biological manifestation remain unclear. There are no histological findings that are typical of RA and distinguish it from other inflammatory arthropathies [3]. The only exception is the formation of T–B cell follicles, which sometimes form germinal-like centres [1416]. It was also suggested that patients with such focal lymphoid aggregates represented a greater degree of immunological activation and greater potential for articular destruction [14]. Microscopic evaluation of rheumatoid synovium may demonstrate the existence of at least three histological types [17]. Lymphocytic clusters were found in a subgroup of RA patients. Some of these clusters resembled germinal centre-like structures with a central accumulation of B cells surrounded by T cells. A few RA patients had necrobiotic granulomas with a fibrinoid, necrotic centre lined with a collar of histiocytes, rarely with giant cells. The coexistence of follicular synovitis and granulomatous necrobiosis was not observed in the same samples. The remaining patients had only a diffuse infiltrate of mononuclear cells with no further morphological organization [17].

Each of the histological forms of rheumatoid synovitis might be characterized by a specific pattern of cytokine mRNA expression in the synovium [17]. The purpose of this study was to explore whether serum concentrations of MMPs and/or their inhibitors were also associated with the histological appearance of the disease.


    Materials and methods
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Patients
Synovial tissue and blood samples were obtained from 37 patients with active RA who met the 1987 American College of Rheumatology criteria for the diagnosis of RA [18]. Tissue specimens were taken during total hip or knee joint replacement surgery. Samples obtained from 30 osteoarthrosis (OA) patients during total hip arthroplasty were used as a control. Table 1Go shows the characteristics of the patient groups.


View this table:
[in this window]
[in a new window]
 
TABLE 1. Characteristics of patient populations (mean±S.D.)

 

Clinical and laboratory evaluation
The analysis included the duration of morning stiffness, the number of tender joints (Ritchie index) [19], the number of swollen joints, the erythrocyte sedimentation rate (ESR) and the rheumatoid factor level.

Histopathological assessment
Synovial tissue specimens were stained with haematoxylin and eosin. The density of the cell infiltrate and the topographical organization of mononuclear cells were analysed and classified as described previously [17]. Samples were assessed by one pathologist (BC), who was blind to the clinical and laboratory data.

Serum sample preparation
Blood specimens were clotted for 30 min and then centrifuged for 10 min at 1000 g. Serum aliquots were frozen at -80 °C immediately after sample collection.

Measurement of serum MMPs and TIMPs
Serum concentrations of MMP-1, MMP-3, MMP-9, TIMP-1 and TIMP-2 were measured with a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) (Biotrak; Amersham Pharmacia Biotech, Little Chalfont, UK) according to the manufacturer's instructions. The sensitivities were 1.7 ng/ml for MMP-1, 2.35 ng/ml for MMP-3, 0.6 ng/ml for MMP-9, 1.25 ng/ml TIMP-1 and 3.0 ng/ml for TIMP-2.

Statistical analysis
Normally distributed clinical data were analysed with the unpaired Student's t-test. The Mann–Whitney U-test was employed to analyse differences between non-normally distributed data on MMPs and TIMPs. Probabilities of differences in frequency distributions were assessed with Fisher's exact test. The analysis of correlations between variables was based on Spearman's rank test. P<0.05 was considered statistically significant.


    Results
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Histological evaluation
The morphological analysis of synovial samples from RA patients revealed mononuclear cell infiltrates. These varied in density, were of perivascular and interstitial types and consisted mainly of lymphocyte- and macrophage-like cells. Twenty-two RA synovium tissues presented only diffuse lymphocyte infiltration with no further microanatomical organization. Specimens of this type were categorized as diffuse synovitis. Follicular aggregates of lymphocytes with germinal centre-like structures were present in 15 samples. These tissues were classified as follicular synovitis. In rheumatoid synovia we also found varied capillary neoangiogenesis, proliferation of the synovial lining layer and rare giant-like cells. The formation of necrobiotic granulomas was not observed. The synovial samples from the OA control group were characterized by mild mononuclear cell infiltrates. Figure 1Go shows examples from patients with OA and two different subtypes of rheumatoid synovitis.



View larger version (109K):
[in this window]
[in a new window]
 
FIG. 1. Histology of RA and OA synovia. Tissue samples were assessed for cell infiltrate density and topographical organization. Examples are presented for the three groups of patients. Original magnification x200. (A) Twenty-two RA synovium specimens demonstrated diffuse lymphocyte infiltrates without specific microanatomical organization. (B) Lymphocytic follicular aggregates were found in 15 samples. (C) Thirty synovia from the OA control group were characterized by moderate mononuclear cell infiltrates.

 

Clinical and radiological findings
No significant differences in sex ratio, age or disease duration were observed between patients with the two morphological types of RA and those with OA. The ESR was higher in the RA than in the OA group (P<0.001) and higher in patients with follicular synovitis than in those with diffuse infiltration (P<0.05) (Table 1Go). The number of swollen joints was higher in patients with the follicular type of RA than in those with the diffuse type (P<0.01). Radiologically more advanced joint destruction (stage III or IV according to Steinbrocker's criteria) was more frequent in the group of patients with follicular synovitis than in the group with diffuse infiltration (P<0.05) (Table 1Go). No other clinical parameters of disease activity differed significantly between the histological variants of RA.

All patients were receiving non-steroidal anti-inflammatory drugs. Sulphasalazine was used in the therapy of five (22.7%) and two (13.3%) RA patients with the diffuse and follicular type of synovitis respectively during the last 3 months before surgery (difference not significant) (Table 1Go). Seven (31.8%) RA patients with diffuse synovitis were being treated with methotrexate compared with 12 (80.0%) patients with the follicular histological form of the disease (P<0.01). Four (18.2%) and five (33.3%) RA patients with the diffuse and follicular type of synovitis respectively were receiving oral steroids (difference not significant). No patients received steroid injections in last 3 months before surgery.

Serum MMP concentrations
A two-site ELISA sandwich technique was used to measure the serum concentrations of MMPs. Our main interest was whether the levels of MMPs differed between patients with distinct histological types of synovitis. As shown in Fig. 2Go, the amounts of MMP-1 in serum were higher in patients with RA and the diffuse and follicular types of synovitis than in OA patients (P<0.001, P<0.01 and P<0.001 respectively). MMP-1 reached the highest concentration in patients with the follicular type of synovitis, differentiating them from those with the diffuse histological type of the disease (P<0.05).



View larger version (14K):
[in this window]
[in a new window]
 
FIG. 2. Serum concentration of interstitial collagenase (MMP-1) in patients, measured with an ELISA sandwich technique. The results are shown as box plots with medians, 25th and 75th percentiles, and whiskers representing the 10th and 90th percentiles. Concentrations of MMP-1 in serum were higher in RA and in the diffuse or follicular type of synovitis than in OA patients. The highest MMP-1 concentration was in patients with the follicular type, distinguishing them from those with the diffuse type.

 
Like the MMP-1 levels, the serum levels of MMP-3 were elevated in RA and in both morphological forms of synovitis compared with OA (P<0.001 for all comparisons) (Fig. 3Go). MMP-3 was the dominant metalloproteinase in follicular synovitis and clearly differentiated these patients from those with only diffuse infiltrates (P<0.01).



View larger version (14K):
[in this window]
[in a new window]
 
FIG. 3. Serum concentration of stromelysin-1 (MMP-3), measured and reported as described in the legend of Fig. 2Go. The serum levels of MMP-3 were greater in RA and in both morphological forms of synovitis than in OA. MMP-3 was the dominant MMP in follicular synovitis and clearly differentiated these patients from patients with diffuse infiltrates.

 
Serum levels of MMP-9 were also increased in RA patients and in patients with both histological types of the disease in comparison with OA patients (P<0.001 for all comparisons) (Fig. 4Go). The highest serum concentration of MMP-9 correlated with the presence of follicular lymphocytic aggregates and was greater than the concentration in patients with the diffuse type of disease (P<0.001). This metalloproteinase distinguished clearly between the two variants of rheumatoid synovitis.



View larger version (15K):
[in this window]
[in a new window]
 
FIG. 4. Serum concentration of gelatinase B (MMP-9), measured and reported as described in the legend of Fig. 2Go. Serum concentrations of MMP-9 were increased in RA and in both histological types of RA in comparison with OA. The highest serum concentration of MMP-9 correlated with the presence of the follicular form of synovitis, and the difference in concentration clearly distinguished the two variants of rheumatoid synovitis.

 

Serum TIMP concentrations
Serum concentrations of TIMPs were also measured with a two-site ELISA sandwich method. Like the MMP levels, the serum levels of TIMP-1 were higher in RA patients and in patients with the diffuse and follicular morphological forms of rheumatoid synovitis than in OA patients (P<0.001 for all comparisons) (Fig. 5Go). TIMP-1 reached the highest concentration in patients with the follicular type of synovitis and clearly differentiated these patients from patients with diffuse infiltrates (P<0.05).



View larger version (14K):
[in this window]
[in a new window]
 
FIG. 5. Serum concentration of TIMP-1, measured and reported as described as in the legend of Fig. 2Go. Serum levels of TIMP-1 were elevated in RA and the diffuse and follicular morphological forms of rheumatoid synovitis compared with OA. The highest concentration of TIMP-1 was in patients with the follicular type of synovitis, and the difference in concentration clearly differentiated these patients from those with diffuse infiltrates.

 
Serum concentrations of TIMP-2 were also higher in patients with RA or follicular synovitis than in OA patients (P<0.01 for both comparisons) (Fig. 6Go). However, the TIMP-2 level did not differ significantly between the two histological patterns of RA.



View larger version (14K):
[in this window]
[in a new window]
 
FIG. 6. Serum concentration of TIMP-2, measured and reported as described as in the legend of Fig. 2Go. The serum concentration of TIMP-2 was higher in patients with RA or follicular synovitis than in OA patients. The TIMP-2 concentration did not differ significantly between the two distinct histological patterns of RA.

 
The analysis of the concentrations of metalloproteinases and their inhibitors showed that follicular RA synovitis, contrary to the diffuse form, is associated with relatively high serum concentrations of MMP-1, MMP-3, MMP-9 and TIMP-1. Therefore, serum levels of these MMPs and their inhibitors seem to be associated with the histological manifestation of the disease.

Correlations between clinical data and serum MMP and TIMP levels
Table 2Go shows the correlations among clinical parameters of disease activity and between these variables and serum MMP and TIMP concentrations in RA patients.


View this table:
[in this window]
[in a new window]
 
TABLE 2. Correlations between serum concentrations of MMPs and/or TIMPs and clinical parameters in all 37 RA patients

 
As shown in Table 1Go, about 64 and 80% of RA patients with diffuse and follicular synovitis respectively were seropositive. No correlations were found between rheumatoid factor and any MMP or TIMP concentration.

Concentration ratios of MMPs to TIMPs
As shown in Table 3Go, the calculated concentration ratios of MMP-1 to TIMP-1 or TIMP-2 did not differ significantly between OA and RA patients with the two histological patterns of synovitis. The concentration ratios of MMP-3, MMP-9 and total measured MMPs to TIMP-1, TIMP-2 and total measured TIMPs were higher in RA patients than in OA patients (P<0.001 for all comparisons), but were especially elevated among patients with the follicular type of rheumatoid synovitis. However, significant differences between the two histological types of RA were observed only for the ratios MMP-9/TIMP-1, MMP-9/TIMP-2 and total MMPs/total TIMPs (P<0.05, P<0.01 and P<0.05 respectively).


View this table:
[in this window]
[in a new window]
 
TABLE 3. Concentration ratios of MMPs to TIMPs

 


    Discussion
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Several studies have indicated the genetic, clinical and biological heterogeneity of RA [1014]. Also, the analysis of RA synovium by conventional histology has revealed the existence of at least three distinct morphological patterns of rheumatoid synovitis [17]. In the previous study [17], diffuse infiltrates of lymphocytes and macrophages with no characteristic microanatomical organization were found in about half of the samples. One-third of the specimens revealed the presence of lymphocytic aggregates. These structures resembled germinal centres and displayed a central accumulation of B cells surrounded by T cells. Such clusters were surrounded by a diffuse infiltration of mononuclear cells. The presence of such germinal centres in the synovium, which is not a lymphoid tissue, emphasizes the role of the immune system in RA. It also suggests that antigens and antigen recognition are involved in the pathogenesis of this disease [13]. Only a few RA samples displayed the presence of necrobiotic granulomas. In these rare specimens, a collar of histiocytes, sometimes with giant cells, surrounded the fibrinoid necrotic centres [17]. The diffuse type of synovitis was characterized by low levels of transcription of mRNAs for interferon {gamma} (IFN-{gamma}), interleukin (IL)-4, IL-1ß and tumour necrosis factor {alpha} (TNF-{alpha}). Specimens categorized as follicular demonstrated elevated production of IFN-{gamma}, IL-1ß and TNF-{alpha} but IL-4 was almost undetectable. The third histological type of synovitis, with necrobiotic granuloma formation, revealed the highest level of transcription of IFN-{gamma}, IL-1ß, TNF-{alpha} and, surprisingly, of IL-4. Diffuse synovitis with a Th0-like cytokine pattern was observed among patients with less active RA, 50% of whom were seronegative for the presence of rheumatoid factor. The Th0 pattern of cytokine production suggests that the T-cell response was not highly differentiated in these patients. The follicular type of synovitis, in which there was a Th1-like pattern of cytokine production, was characteristic of seropositive patients with more active disease. Least common was granulomatous synovitis with a mixed Th1/Th2 cytokine pattern, which was found in a group of patients who were mostly seropositive and had the most active RA [17].

In the present study, we were able to distinguish only two of the morphological forms of rheumatoid synovitis described in the report referred to above [17]. Almost two-thirds of the RA synovium tissues were characterized by diffuse mononuclear cell infiltrates with no further microanatomical organization. Follicular clusters of lymphocytes with germinal centre-like structures were found in the remaining specimens. We did not find necrobiotic granulomas. However, in the previous study [17] these were very rare.

MMPs and TIMPs play an important role in the remodelling of the articular tissues [46, 9]. MMPs are responsible for the proteolytic degradation of extracellular matrix components. They are produced by several types of cell, such as chondrocytes, fibroblasts and macrophages [57, 20]. It was demonstrated that their synthesis is stimulated by cytokines such as IL-1 and TNF-{alpha} [5, 6, 21]. The action of MMPs is regulated by TIMPs, the production of which is stimulated by cytokines such as transforming growth factor ß, IL-6 and IL-11 [5, 6, 22]. The aim of the present study was to explore whether the serum concentrations of MMPs and their inhibitors are associated with the histological appearance of the disease. Our main interest was whether the concentrations of MMPs and/or TIMPs might identify patients with distinct morphological types of rheumatoid synovitis.

Interstitial collagenase (MMP-1), produced mainly by synovial fibroblasts [20, 23], plays an important role in the degradation of articular cartilage and synovium [5, 6, 9]. Previous investigators have shown that, in RA, MMP-1 is present not only in synovium [20, 24, 25] but also in synovial fluid [25] and serum [23, 25]. However, only some of the previous work has shown that its concentration in RA synovial fluid [26] or serum [27, 28] differs significantly from concentrations in controls. That MMP-1 is expressed not only in patients with established erosive RA but also in patients with early arthritis implies that this protease may serve as a marker of the very early stage of the disease [29]. Our study confirms that the level of MMP-1 in serum is elevated in RA patients. Furthermore, we found that MMP-1 reached its highest concentration in patients with the follicular type of synovitis, differentiating them from those with diffuse synovitis.

We also demonstrated that the serum concentration of this protease correlated with MMP-3, MMP-9 and clinical markers of disease activity, such as ESR and the duration of morning stiffness. Among the group of 15 patients with the follicular type of the disease and with more advanced joint destruction, we also found significant correlations between the serum level of MMP-1 and the Ritchie index (r=0.573, P=0.0252) and the number of swollen joints (r=0.555, P=0.0312) (data not shown). In the case of patients with the diffuse type of synovitis and for all 37 RA patients, these correlations were not significant (data not shown). Therefore, MMP-1 may be more a marker of joint damage than of disease activity.

Stromelysin-1 (MMP-3) is known to degrade components of the extracellular matrix, including proteoglycans, gelatin, fibronectin, laminin and various types of collagens [5, 6, 9, 23]. It is also an activator of pro-MMPs, such as MMP-1 and MMP-9. This protease is produced mainly by fibroblasts [20]. Several studies have revealed that MMP-3 in RA is expressed in large amounts in synovium [20, 24], synovial fluid [26] and serum [23, 27, 28, 3032]. It was also shown that the concentration of MMP-3 in RA synovial fluid correlated with that in serum [3234]. Therefore, the serum concentration of MMP-3 may be a useful marker of inflammation activity in the joints of patients with RA. In our study, the serum level of MMP-3, like that of MMP-1, was also greater in RA than in OA patients. In particular, MMP-3 was the dominant metalloproteinase in follicular synovitis and could differentiate these patients clearly from those with only diffuse infiltrates. It was shown that the serum MMP-3 concentration correlated with the ESR and swollen joint count [30, 35, 36]. We demonstrated that the serum concentration of MMP-3 is also associated with the duration of morning stiffness, the Ritchie index and MMP-1 and MMP-9 concentrations. Others have also shown a correlation of MMP-1 with MMP-3 in RA synovial fluid [26]. These results suggest that the follicular histological form of RA can be considered as the more active form of the disease, and that the MMP-3 concentration could be a useful marker for identifying this form of RA. The levels of MMP-3 in the serum of RA patients, even during the early stages of the disease, were higher than those in controls, and appeared to increase as the disease progressed [32, 37, 38]. This suggests that the assessment of serum MMP-3 may be an important tool in the diagnosis of early onset of RA. Suppression of MMP-3 production might be an effective therapeutic approach for patients with early RA.

The serum concentration of gelatinase B (MMP-9), produced mainly by granulocytes [7, 39], was elevated in RA in comparison with OA patients. Other studies showed that MMP-9 was abundant in the RA synovium [7, 40] and found that its levels were increased in RA synovial fluid [7, 26, 40] and serum [7, 40] compared with controls. In our study the highest serum concentration of MMP-9 correlated with the presence of the follicular form of synovitis, in which the concentration was greater than in patients with the diffuse type of disease. This MMP discriminated clearly between these two variants of rheumatoid synovitis. Correlation of MMP-9 with disease activity markers such as ESR and the number of swollen joints seems to confirm the suggestion that RA is more severe in patients with the follicular type of synovitis.

The activity of MMPs is regulated by proenzyme production and/or by the activation of their endogenous inhibitors. There are at least two TIMPs. TIMP-1, the most widely distributed one, suppresses the activity of all MMPs [5, 6]. The presence of TIMP-1 in synovium [5, 6] and in increased amounts in RA synovial fluid [26, 32] or serum [23, 27, 32] has been shown in other studies. On the other hand, some investigators detected very similar levels of TIMP-1 in sera of RA and OA patients [28, 30]. In the present work we showed that the serum levels of TIMP-1, like those of the MMPs we studied, were elevated in RA patients compared with OA patients. Furthermore, TIMP-1 reached its highest concentration in patients with the follicular type of synovitis. Other studies showed that TIMP-1 correlated with ESR [30]. In our study it also correlated with the Ritchie index and the number of swollen joints. Up-regulation of TIMP-1 synthesis, especially in patients with the follicular form of rheumatoid synovitis, might be responsible for the suppression of synovium and cartilage destruction in patients with severe activity of the disease.

Like concentrations of TIMP-1, serum concentrations of TIMP-2 were also higher in patients with RA and with follicular synovitis than in OA patients. However, the TIMP-2 level did not differ significantly between the two histological patterns of RA. Others have also shown a higher serum concentration of TIMP-2 in RA than in controls [27].

Some studies suggest that the articular destruction in RA may be caused by the alteration in the balance between MMPs and TIMPs in favour of MMPs [7, 26, 33]. In our study, the calculated concentration ratios of MMP-3, MMP-9 and the ratios of total measured MMPs to TIMP-1, TIMP-2 and total measured TIMPs were higher in RA patients than in OA patients. They were especially increased in patients with follicular synovitis. However, significant differences between the morphological forms of RA were observed only for the ratios MMP-9/TIMP-1, MMP-9/TIMP-2 and total MMPs/total TIMPs. The analysis of ratios of individual MMPs or total measured MMPs to individual TIMPs or total measured TIMPs suggests that the relative production of TIMPs is decreased in RA compared with OA, especially in patients with the follicular type of synovitis. These data should be considered cautiously because we did not measure other proteinases that may be involved in the process of articular tissue destruction, or other inhibitors.

Radiological analysis demonstrated that more advanced joint destruction was more frequent among patients with follicular synovitis, characterized by higher levels of MMPs and TIMP-1 measured by us. Other investigators have also observed correlations of serum concentrations of MMP-3 and TIMP-1 with disease progression [32].

The analysis of the treatment regimens revealed that methotrexate (MTX) was more often used by patients with follicular synovitis than by those with diffuse synovitis. There is evidence that MTX may decrease the density of the mononuclear cell infiltration in RA synovium [4142]. It was suggested that MTX has an antiangiogenic effect and may reduce joint inflammation through the suppression of the growth of small blood vessels in the synovium, which is related to mononuclear cell migration and the proliferation of synovial tissue [4345]. However, there is also evidence that MTX does not influence cell density significantly in rheumatoid synovium [46, 47]. Moreover, it has also been shown that the density of the mononuclear cell infiltrate is higher in RA patients treated with MTX [48]. We are unaware of any data suggesting an effect of MTX on the formation of follicular structures in rheumatoid synovium.

Methotrexate has also been shown to reduce MMP-1 and MMP-3 production [46, 47, 49] and increase TIMP-1 production [50]. However, some studies suggest that MTX does not have a significant influence on MMP-3 [46] or TIMP-1 production [46, 49]. In our study we found that measured serum concentrations of MMPs and TIMPs and MMP/TIMP ratios were higher in patients with the follicular type of synovitis than in those with diffuse synovitis. This was observed despite more frequent MTX treatment in the group of patients with the follicular form than in those with the diffuse histological form of RA. Therefore, we surmise that the more frequent use of MTX in our patients with follicular than in the group with diffuse synovitis simply suggests greater activity of the disease in the former group of patients.

There were no other significant differences in treatment between the two RA groups that could have influenced the histological appearance of rheumatoid synovitis or the production of MMPs or TIMPs. No patients had received steroid injections in the 3 months before surgery.

Our finding that the distinct morphological appearances of synovitis are associated with different levels of serum MMPs and TIMP-1 confirms the heterogeneity of RA. We also observed correlations of serum MMP and TIMP concentrations with laboratory and clinical parameters of disease activity. Therefore, not only are MMP-1, MMP-3, MMP-9 and TIMP-1 good indicators of disease activity in RA but they might also predict the histological manifestation of the disease. The distinct histological, metalloproteinase and TIMP-1 patterns observed in RA patients in our study suggest the possibility of different responses to therapy regimens. However, a longitudinal study of patients at various stages in the disease process is clearly indicated.


    Acknowledgments
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
We thank our colleagues in the Department of Orthopaedic Surgery for providing tissue specimens.


    Notes
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Correspondence to: P. A. Klimiuk, Department of Rheumatology and Internal Diseases, Medical University of Bialystok, M. C. Sklodowskiej 24a, 15-276 Bialystok, Poland Back


    References
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 

  1. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol1999;26:717–9.[ISI][Medline]
  2. Fujinami M, Sato K, Kashiwazaki S, Aotsuka S. Comparable histological appearance of synovitis in seropositive and seronegative rheumatoid arthritis. Clin Exp Rheumatol1997;15:11–7.[ISI][Medline]
  3. Hale LP, Haynes BF. Pathology of rheumatoid arthritis and associated disorders. In: Koopman WJ, ed. Arthritis and allied conditions. A textbook of rheumatology. Baltimore: Williams & Wilkins, 1997:993–1016.
  4. Harris ED. Rheumatoid arthritis. Philadelphia: W. B. Saunders, 1997.
  5. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: W. B. Saunders, 1997:851–97.
  6. Nagase H, Okada Y. Proteinases and matrix degradation. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: W. B. Saunders, 1997:323–41.
  7. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum1996;39:1576–87.[ISI][Medline]
  8. Klimiuk PA, Yang H, Goronzy JJ, Weyand CM. Production of cytokines and metalloproteinases in rheumatoid arthritis is T cell dependent. Clin Immunol1999;90:65–78.[ISI][Medline]
  9. Matrisian L. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet1990;6:121–5.[ISI][Medline]
  10. Malone DG, Wahl SM, Tsokos M, Cattell H, Decker JL, Wilder RL. Immune function in severe, active rheumatoid arthritis. A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and synovial tissue immunohistologic characteristics. J Clin Invest1984;74:1173–85.[ISI][Medline]
  11. Rooney M, Condell D, Quinlan W et al. Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum1988;31:956–63.[ISI][Medline]
  12. Sany J. Clinical and biological polymorphism of rheumatoid arthritis. Clin Exp Rheumatol1994;12(Suppl. 11):S59–61.
  13. Weyand CM, Klimiuk PA, Goronzy JJ. Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes. Springer Semin Immunopathol1998;20:5–22.[ISI][Medline]
  14. Yanni G, Whelan A, Feighery C et al. Contrasting levels of in vitro cytokine production by rheumatoid synovial tissues demonstrating different patterns of mononuclear cell infiltration. Clin Exp Immunol1993;93:387–95.[ISI][Medline]
  15. Kim HJ, Krenn V, Steinhauser G, Berek C. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol1999;162:3053–62.[Abstract/Free Full Text]
  16. Wagner UG, Kurtin PJ, Wahner W et al. The role of CD8+ CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis. J Immunol1998;161:6390–7.[Abstract/Free Full Text]
  17. Klimiuk PA, Goronzy JJ, Bjornsson J, Beckenbaugh RD, Weyand CM. Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol1997;151:1311–9.[Abstract]
  18. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum1988;31:315–24.[ISI][Medline]
  19. Ritchie DM, Boyle JA, McInnes JM et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med1968;37:393–406.[Medline]
  20. Tetlow LC, Lees M, Woolley DE. Comparative studies of collagenase and stromelysin-1 expression by rheumatoid synoviocytes in vitro. Virchows Arch1995;425:569–76.[ISI][Medline]
  21. Lefebvre V, Peeters-Joris C, Vaes G. Modulation by interleukin 1 and tumor necrosis factor {alpha} of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim Biophys Acta1990;1052:366–78.[ISI][Medline]
  22. Hermann JA, Hall MA, Maini RN, Feldman M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum1998;41:1388–97.[ISI][Medline]
  23. Manicourt DH, Fujimoto N, Obata K, Thonar EJMA. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Arthritis Rheum1995;38:1031–9.[ISI][Medline]
  24. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum1991;34:1076–84.[ISI][Medline]
  25. Maeda S, Sawai T, Uzuki M et al. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann Rheum Dis1995;54:970–5.[Abstract]
  26. Yoshihara Y, Nakamura H, Obata K et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis2000;59:455–61.[Abstract/Free Full Text]
  27. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer1994;70:506–12.[ISI][Medline]
  28. Keyszer G, Lambiri I, Keysser M et al. Matrix metalloproteinases, but not cathepsins B, H and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity. Z Rheumatol1998;57:392–8.[ISI][Medline]
  29. Cunnane G, FitzGerald O, Hummel KM, Gay RE, Gay S, Bresnihan B. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology1999;38:34–42.[Free Full Text]
  30. Keyszer G, Lambiri I, Nagel R et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol1999;26:251–8.[ISI][Medline]
  31. Kotajima L, Aotsuka S, Fujimani M et al. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. Clin Exp Rheumatol1998;16:409–15.[ISI][Medline]
  32. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum1995;38:969–75.[ISI][Medline]
  33. Ishiguro N, Ito T, Obata K, Fujimoto N, Iwata H. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol1996;23:1599–604.[ISI][Medline]
  34. Taylor DJ, Cheung NT, Dawes PT. Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis1994;53:768–72.[Abstract]
  35. Ichikawa Y, Yamada C, Horiki T, Hoshina Y, Uchiyama M. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clin Exp Rheumatol1998;16:533–40.[ISI][Medline]
  36. So A, Chamot AM, Peclat V, Gerster JC. Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatology1999;38:407–10.[Abstract]
  37. Posthumus MD, Limburg PC, Westra J et al. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology1999;38:1081–7.[Abstract/Free Full Text]
  38. Yamanaka H, Matsuda Y, Tanaka M et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum2000;43:852–8.[ISI][Medline]
  39. Bläser J, Triebel S, Maasjosthusmann U et al. Determination of metalloproteinases, plasminogen-activators and their inhibitors in synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis. Clin Chim Acta1996;244:17–33.[ISI][Medline]
  40. Gruber BL, Sorbi D, French DL et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol1996;78:161–71.[ISI][Medline]
  41. Balsa A, Gamallo C, Martin-Mola E, Gijon-Banos J. Histologic changes in rheumatoid synovitis induced by naproxen and methotrexate. J Rheumatol1993;20:1472–7.[ISI][Medline]
  42. Dolhain RJ, Tak PP, Dijkmans BA, De Kuiper P, Breedveld FC, Miltenburg AM. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol1998;37:502–8.[ISI][Medline]
  43. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum1989;32:1065–73.[ISI][Medline]
  44. Nagashima M, Wauke K, Hirano D et al. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology2000;39:1255–62.[Abstract/Free Full Text]
  45. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum1998;41:1258–65.[ISI][Medline]
  46. Firestein GS, Paine MM, Boyle DL. Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression. Arthritis Rheum1994;37:193–200.[ISI][Medline]
  47. Kraan MC, Reece RJ, Barg EC et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum2000;43:1820–30.[ISI][Medline]
  48. Haraoui B, Pelletier JP, Cloutier JM, Faure MP, Martel-Pelletier J. Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. Arthritis Rheum1991;34:153–63.[ISI][Medline]
  49. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier JM, Pelletier JP. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest1994;70:807–15.[ISI][Medline]
  50. Seitz M, Dayer JM. Enhanced production of tissue inhibitor of metalloproteinases by peripheral blood mononuclear cells of rheumatoid arthritis patients responding to methotrexate treatment. Rheumatology2000;39:637–45.[Abstract/Free Full Text]
Submitted 21 December 2000; Accepted 20 July 2001